BASF ups EOA prices again

BASF EOA

Related tags Ethanolamine

BASF has changed what it charges for ethanolamines (EOA) in Europe for the third time this year. 

The German chemicals giant announced that it is increasing what it charges for EOAs – which are used in the production of active pharmaceutical ingredients, agrochemicals, cement additives and a variety of other industrial applications – earlier today.

Effectively immediately BASF will charge €70 per metric ton of monoethanolamine (MEOA), diethanolamine and triethanolamine, in a move that will be applied to existing supply contracts as soon as terms and conditions allow.

BASF – which makes EOA at its plants in Ludwigshafen, Germany; Antwerp, Belgium; and Nanjing, China – did not specify the reason for the increase.

However, speaking to in-Pharmatechnologist.com when it last announced changes to its EOA prices in February​ the firm cited rising raw materials costs – specifically ethylene and ammonia – as the key factor.

At the time BASF increased its prices for diethanolamine (DEOA) and triethanolamine (TEOA) to €90 per ton, suggesting that it reduced it again in the months between then and today's increase.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars